AnaptysBio, Inc.
Prices may be delayed up to 15 min. Not investment advice. News volume: articles in the 4Search index each day.
Key statistics
Against its peers
Compare in full ›| ANAB | 8SJ.F | ABCL | 0RC6.IL | IMCR | 688177.SS | |
|---|---|---|---|---|---|---|
| Market cap | 1.42B | 1.84B | 3.98B | 1.21B | 1.51B | 7.38B |
| P/E (TTM) | — | — | — | 60.5 | — | — |
| Forward P/E | 10.5 | — | -16.1 | — | -37.7 | -26.2 |
| Price/book | 133.5 | 2.4 | 4.2 | 5.7 | 3.6 | 171.3 |
| Dividend yield | — | — | — | 2.09% | — | — |
| 1-year change | +98.88% | −40.07% | +159.70% | −9.53% | −2.50% | −34.43% |
| Today | −0.46% | +1.70% | +0.82% | +1.32% | −2.66% | +2.95% |
The closest companies by business and industry (Biotechnology). Prices may be delayed up to 15 min.
Latest news
All ANAB news ›Alopecia Areata Pipeline 2026: Inside the Clinical Trial Landscape, Therapeutic Assessment, and Key Companies Involved | Pfizer, Legacy Healthcare, AnaptysBio, Eli Lilly and Company, Incyte, Novartis
Alopecia Areata Pipeline 2026: Inside the Clinical Trial openPR.com Alopecia Areata Pipeline 2026: Inside the Clinical Trial Landscape, Therapeutic Assessment, and Key Companies Involved | Pfizer, Legacy Healthcare, AnaptysBio, Eli Lilly…
AnaptysBio quickly drops amid hearing on GSK/Tesaro contract breach
Seeking Alpha BrianAJackson/iStock via Getty Images AnaptysBio (ANAB) fell 8% amid a hearing in Delaware over contract breach litigation with GSK and its Tesaro unit. GSK ADRs rose 2.4%. The hearing in Delaware Chancery Court start
AnaptysBio (NASDAQ:ANAB) Stock Price Up 5.4% – What’s Next?
Posted by Michael Walen on Oct 21st, 2026 AnaptysBio, Inc. (NASDAQ:ANAB – Get Free Report) shares traded up 5.4% on Wednesday. The company traded as high as $47.88 and last traded at $47.8890. Approximately 39,486 shares traded hands…
AnaptysBio (ANAB) Shares Drop 8% Amid Delaware Breach of Contract Lawsuit Hearing
On October 20, 2026, AnaptysBio Inc (NASDAQ: ANAB) saw its stock decline 8% as a Delaware court hearing began over a breach of contract lawsuit filed against GSK and its Tesaro unit. The litigation centers on allegations that GSK violated…
AnaptysBio gains as GSK granted FDA label expansion for Jemperli
AnaptysBio (ANAB) stock rises as partner GSK (GSK) wins FDA label expansion for the companys' jointly developed cancer therapy Jemperli in rectal cancer. Read more here. AnaptysBio (ANAB) traded higher on Monday after its partner GSK (GSK)…
AnaptysBio: Fully Valued; With Major Litigation Uncertainty
AnaptysBio: Fully Valued — With Major Litigation Uncertainty (NASDAQ:ANAB) Seeking Alpha - AnaptysBio has pivoted to a royalty management model, with Jemperli royalties as its primary value driver. - Jemperli’s robust FDA approval…
Why This IPO Stock, An AnaptysBio Spinoff, Just Surged
Allison Gatlin covers biotechnology, pharmaceuticals and medical technology. She also oversees coverage of top-performing companies for Investor's Business Daily's The New America page. Allison has worked for Investor's Business Daily…
AnaptysBio (ANAB) – Investment Analysts’ Weekly Ratings Changes
Several analysts have recently updated their ratings and price targets for AnaptysBio (NASDAQ: ANAB): 10/4/2026 – AnaptysBio was downgraded by Wall Street Zen from “buy” to “hold”. 9/30/2026 – AnaptysBio had its price target lowered by…
From the 4Search news index, newest first.
In the news
Mentioned with
People in the coverage
Themes
Most coverage from
- seekingalpha.com3
- themarketsdaily.com2
- gurufocus.com1
- investors.com1
- marketbeat.com1
Finance and business coverage in the 4SEARCH.business news index: articles that name it in the headline, or in the text beside its ticker. Sentiment is the index's own reading of the latest 8 articles, not a forecast.